212 related articles for article (PubMed ID: 28398294)
1. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study.
Shih HJ; Kao MC; Tsai PS; Fan YC; Huang CJ
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):328-333. PubMed ID: 28398294
[TBL] [Abstract][Full Text] [Related]
2. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944
[TBL] [Abstract][Full Text] [Related]
3. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment.
Vargas-Santos AB; Peloquin CE; Zhang Y; Neogi T
JAMA Intern Med; 2018 Nov; 178(11):1526-1533. PubMed ID: 30304329
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol and the incidence of bladder cancer: a Taiwan national retrospective cohort study.
Chen CJ; Hsieh MC; Liao WT; Chan YT; Chang SJ
Eur J Cancer Prev; 2016 May; 25(3):216-23. PubMed ID: 25830898
[TBL] [Abstract][Full Text] [Related]
5. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):373-378. PubMed ID: 29273728
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.
Singh JA; Ramachandaran R; Yu S; Curtis JR
BMC Cardiovasc Disord; 2017 Mar; 17(1):76. PubMed ID: 28288564
[TBL] [Abstract][Full Text] [Related]
7. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
[TBL] [Abstract][Full Text] [Related]
8. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of cancer among gout patients: a nationwide population study.
Kuo CF; Luo SF; See LC; Chou IJ; Fang YF; Yu KH
Joint Bone Spine; 2012 Jul; 79(4):375-8. PubMed ID: 22088929
[TBL] [Abstract][Full Text] [Related]
10. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study.
Kok VC; Horng JT; Chang WS; Hong YF; Chang TH
PLoS One; 2014; 9(6):e99102. PubMed ID: 24897240
[TBL] [Abstract][Full Text] [Related]
11. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
[TBL] [Abstract][Full Text] [Related]
12. Gout, allopurinol use, and heart failure outcomes.
Thanassoulis G; Brophy JM; Richard H; Pilote L
Arch Intern Med; 2010 Aug; 170(15):1358-64. PubMed ID: 20696962
[TBL] [Abstract][Full Text] [Related]
13. Allopurinol Dose Escalation and Mortality Among Patients With Gout: A National Propensity-Matched Cohort Study.
Coburn BW; Michaud K; Bergman DA; Mikuls TR
Arthritis Rheumatol; 2018 Aug; 70(8):1298-1307. PubMed ID: 29513934
[TBL] [Abstract][Full Text] [Related]
14. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
15. Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study.
Chuang JP; Lee JC; Leu TH; Hidajah AC; Chang YH; Li CY
BMJ Open; 2019 Oct; 9(10):e028892. PubMed ID: 31601586
[TBL] [Abstract][Full Text] [Related]
16. Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis.
Kuo CF; Grainge MJ; Mallen C; Zhang W; Doherty M
Rheumatology (Oxford); 2015 Dec; 54(12):2145-50. PubMed ID: 26170376
[TBL] [Abstract][Full Text] [Related]
17. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
[TBL] [Abstract][Full Text] [Related]
18. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
19. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A
Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
